Recently, Professor Chen Qingjiang, First-Level Inspector of the Henan Provincial Health Commission, Executive President and Deputy Party Secretary of Henan Academy of Medical Sciences, led a team to the Shenzhen-Hong Kong Cell Valley for site visits and discussions. The two sides held in-depth talks on key issues including clinical translation of cell therapy, project collaboration, and pathways for regulatory application and implementation. They reached important consensus on accelerating the translation of research outcomes into clinical practice and exploring a collaborative mechanism for cell therapy clinical research and translation. A new model of deep integration among industry, academia, research, and medicine—driven by clinical demand, supported by technology R&D, and underpinned by industrial implementation—was jointly proposed.

The visiting delegation included Sun Guoming, Executive Director of the Central Plain Nanozyme Laboratory; Zhang Xudong, Director of the Oncology Ward at the First Affiliated Hospital of Zhengzhou University; along with other key research and clinical staff. Representing the Cell Valley Group were Professor Shi Yuanyuan, Chairman and General Manager; Wang Jianxun, Director and Chief Scientist; Sun Rui, Head of Marketing; and Fu Yuchen, Director of the International Medical Service Center, who participated in the reception and symposium discussions.

Accompanied by Professor Shi Yuanyuan, President Chen Qingjiang and his delegation toured the Cell Valley's industrial platform and innovation exhibition area, gaining detailed insight into the group's overall layout and capabilities in cell drug development, process development, quality control, compliant manufacturing, clinical translation, and industrial implementation. The visiting experts spoke highly of the Cell Valley's achievements in cell product process development, standardized manufacturing, regulatory filing support, and full-chain service system construction.

During the symposium, Professor Shi Yuanyuan extended a warm welcome to President Chen and systematically introduced the Cell Valley's integrated service system covering "R&D – manufacturing – quality control – regulatory filing – translation" in cell and gene therapy. He noted that cell therapy is currently at a critical juncture where policies, technologies, and clinical demand are rapidly converging, requiring coordinated efforts from high-level research institutions, clinical centers, and industrial platforms to bridge the "last mile" of translation. The Cell Valley looks forward to strengthening cooperation with Henan Academy of Medical Sciences, the First Affiliated Hospital of Zhengzhou University, and the Central Plain Nanozyme Laboratory, exploring a demonstrative path for cell therapy clinical translation focused on priority disease areas, key projects, and major technology directions, and ultimately forming a replicable and scalable "Henan Model."

    President Chen Qingjiang shared the Henan Academy of Medical Sciences' overall strategy and interim achievements in medical science innovation, result translation, platform development, and regional medical collaboration. He noted that Henan is actively promoting the deep integration of cutting-edge medical technologies with high-level clinical resources, continuously enhancing its capabilities in strategic emerging fields such as cell and gene therapy. He expressed hope that this visit would serve as an opportunity to draw on the Cell Valley's proven experience in cell manufacturing, process development, compliance system building, and industrial translation, further strengthening coordination among research, clinical, and industrial chains, and accelerating the implementation of more high-quality projects in Henan.

    Dr. Zhang Xudong highlighted the comprehensive strengths of the First Affiliated Hospital of Zhengzhou University in oncology diagnosis and treatment, clinical research, patient resources, and standardized management. As a key player in the National Regional Medical Center, the hospital possesses a solid foundation in tumor immunotherapy and clinical trial execution. He expressed anticipation for deeper, practical collaboration with the Cell Valley in clinical protocol design, patient enrollment, efficacy uation, and translational application, thereby driving higher-quality development of cell therapy technologies in major diseases such as cancer.

    Dr. Sun Guoming, Executive Director of the Central Plain Nanozyme Laboratory, stated that the laboratory will actively leverage its role as a cutting-edge interdisciplinary research platform. By fostering convergence between nanotechnology, biomedicine, and clinical translation, the lab aims to precisely align innovative technologies with clinical needs, providing new scientific support for the future translation and application of cell therapy and related frontier technologies.

Looking ahead, all parties will take this visit as a new starting point to strengthen ongoing communication and collaboration, promoting efficient integration of high-quality research, clinical, and industrial resources. They will pursue higher-level cooperation on key breakthroughs in cell therapy technologies, clinical research implementation, and translational application, jointly exploring a regionally exemplary new path for cell therapy translation and injecting fresh momentum into the high-quality development of the biopharmaceutical industry in both the Central Plains region and the Guangdong-Hong Kong-Macao Greater Bay Area.

Profile of Professor Chen Qingjiang

A senior expert in medical management and medical ethics in China, Professor Chen Qingjiang currently serves as First-Level Inspector of the Henan Provincial Health Commission, Executive President and Deputy Party Secretary of Henan Academy of Medical Sciences. He holds the rank of Second-Level Professor, Doctoral Supervisor, and is recognized as a Provincial Outstanding Expert. He also serves as a standing committee member of the Ethics Branch of the Chinese Preventive Medicine Association, vice chairman of relevant committees of the Chinese Hospital Association, vice chairman of the Henan Provincial Ethics Association, vice chairman of the Henan Provincial Hospital Association, and editor-in-chief of the *Journal of Medical Forum*. Professor Chen has led six major national and provincial research projects, published over 20 SCI papers, and received numerous honors including the State Council Special Allowance, the Henan Provincial May Day Labor Medal, the Excellent Worker Award from the Chinese Society of Educational, Scientific, Medical and Cultural Workers' Union, and the National Outstanding Innovation and Entrepreneurship Mentor. He has profound expertise and broad influence in medical science and technology innovation management, high-quality hospital development, and research ethics governance.

Henan Academy of Medical Sciences

    The Henan Academy of Medical Sciences is a public institution directly under the Henan Provincial Government, serving as a novel medical research and development organization and a high-level platform for medical research and achievement translation strategically established in the province. Focusing on medical science and technology innovation, clinical research coordination, result translation and implementation, and high-caliber talent aggregation, the academy is committed to building a medical innovation system that integrates basic research, technology development, clinical validation, and industrial translation—providing critical support for the high-quality development of the life and health industry in Henan and the wider central region of China.

Central Plain Nanozyme Laboratory

    The Central Plain Nanozyme Laboratory is a provincial-level laboratory established under the leadership of the Henan Academy of Medical Sciences. Inaugurated on October 15, 2023, it operates as a novel R&D institution. The laboratory is directed by Yan Xiyun, an academician of the Chinese Academy of Sciences. It focuses on research into nanozymes and related cutting-edge interdisciplinary technologies, aiming to drive innovative applications of new materials and technologies in disease diagnosis, precision medicine, and biomedical translation. Distinguished by its strength in interdisciplinary integration, innovation incubation, and the bridging of clinical translation, the laboratory is a key platform in Henan's strategic push to advance frontier medical science and technology.

The First Affiliated Hospital of Zhengzhou University

    The First Affiliated Hospital of Zhengzhou University is a national high-level, large-scale, grade-A tertiary comprehensive hospital and a vital platform for medical care, education, research, and clinical translation in the central region of China. The hospital possesses exceptional comprehensive strength, a complete disciplinary system, and abundant clinical resources. It holds prominent advantages in oncology, complex and critical diseases, and multidisciplinary collaborative diagnosis and treatment, providing robust support for clinical research on major diseases and the translation of cutting-edge therapeutic technologies.